Company intelligence / Profile preview

Yamo Pharmaceuticals

Ownership: Private
Development stage: Phase 2

Overview

Yamo Pharmaceuticals completed a Phase 2 study of L1-79 in June 2024, with positive topline results announced on July 30, 2024. The study demonstrated statistically significant improvements in the Vineland-3 Socialization Standard Score, with a more than seven-point improvement representing one of the largest statistically significant effects observed to date with a medication in ASD. The drug was generally safe and well-tolerated with no serious adverse events reported. The company is planning to meet with the FDA to discuss Phase 3 plans and file for Breakthrough Therapy designation[3][9].

Therapeutic areas: Psychiatry
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

L1-79

Beyond the preview

Go deeper on Yamo Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yamo Pharmaceuticals.

Explore the full profile